Medaxone (Ceftriaxone Sodium Sesquaterhydrate)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This weakens the cell wall, causing osmotic lysis and death of susceptible Gram‑negative and some Gram‑positive bacteria.

The specific dose and duration of Medaxone are determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Dosing regimens are not standardized in public information.

Safety data for ceftriaxone in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is reserved for situations where the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To request Medaxone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with earlier‑generation cephalosporins, ceftriaxone offers a broader spectrum against Gram‑negative organisms and a longer half‑life, allowing once‑daily dosing. It is often preferred over penicillins for resistant strains, but like all antibiotics, susceptibility testing guides optimal selection.

Medaxone should be stored below 25 °C in its original packaging, protected from moisture and light. After reconstitution, the solution must be used promptly or stored according to the manufacturer’s instructions, typically at refrigerated temperatures for a limited period.

Medaxone is supplied as a sterile powder for injection and is administered by intravenous or intramuscular injection after reconstitution with the appropriate diluent. Administration technique follows standard aseptic procedures and the dosage is set by the treating physician.

Serious adverse events include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and hemolytic anemia. Patients should be monitored for signs of rash, respiratory distress, persistent diarrhea, or unexplained jaundice, and treatment should be stopped if these occur.

Medaxone is contraindicated in individuals with a known hypersensitivity to ceftriaxone or other cephalosporin antibiotics. Neonates ≤28 days should not receive it intravenously with calcium‑containing solutions due to the risk of precipitation and kernicterus.